Results 61 to 70 of about 134,257 (306)

Advances in the Application of Nanomaterials to the Treatment of Melanoma

open access: yesPharmaceutics, 2022
Melanoma can be divided into cutaneous melanoma, uveal melanoma, mucosal melanoma, etc. It is a very aggressive tumor that is prone to metastasis. Patients with metastatic melanoma have a poor prognosis and shorter survival.
Zeqi Wang   +4 more
doaj   +1 more source

Designing a Tablet-based Intervention to Support Self-checking for Melanoma [PDF]

open access: yes, 2015
Postprin
Dennis, Matthew Gordon   +4 more
core   +1 more source

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto   +20 more
wiley   +1 more source

Bilateral Choroidal Metastases as Presentation of Dissemination of Cutaneous Malignant Melanoma

open access: yesCase Reports in Ophthalmological Medicine, 2012
Case Report. A 47-year-old man presented with blurred vision in the right eye. Ophthalmoscopic examination showed several placoid, pigmented lesions in the posterior pole and midperiphery of the retina of both eyes. Results.
S. Fernandez-Perez   +4 more
doaj   +1 more source

Staging of cutaneous melanoma

open access: yesAnnals of Oncology, 2009
The American Joint Committee on Cancer (AJCC) staging of cutaneous melanoma is a continuously evolving system. The identification of increasingly more accurate prognostic factors has led to major changes in melanoma staging over the years, and the current system described in this review will likely be modified in the near future.
Mohr, P   +3 more
openaire   +3 more sources

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

open access: yesAdvanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey   +6 more
wiley   +1 more source

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

open access: yes, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S   +22 more
core   +3 more sources

Single‐Cell Dissection of Tumor‐Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma

open access: yesAdvanced Science, EarlyView.
Autologous tumor‐infiltrating lymphocyte (TIL) therapy shows promising efficacy in acral melanoma, yet determinants of durable response remain unclear. By integrating single‐cell transcriptomics and TCR sequencing, this study reveals that TIL products enriched for T follicular helper and intermediate exhausted T cells establish persistent clonal ...
Chao Zhang   +12 more
wiley   +1 more source

Cure of cutaneous melanoma

open access: yesBMJ, 2006
Melanoma is a deadly but potentially curable disease. Its main cause, and the sole controllable factor, is excessive if intermittent exposure to sunlight, particularly in childhood and adolescence.1,2 The incidence of melanoma is rising faster than for any other cancer and is approximately doubling every decade, although survival rates are improving in
J Meirion, Thomas, Victoria, Giblin
openaire   +3 more sources

Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors

open access: yesAdvanced Science, EarlyView.
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy